Benchmarking and biomarkers: the molecular and technical heterogeneity of prostate cancer

Paul Boutros1

1Ontario Institute for Cancer Research, Toronto, Canada

Abstract

Prostate cancer is the leading non-skin malignancy in men, affecting 1 in 7 men over their lifetime. Today the vast majority of new diagnoses are of localised disease, and these patients have their treatment determined using the clinical/pathological factors of pre-treatment serum PSA levels, T-category and the Gleason Score. These clinical metrics are used to stratify men into low-, intermediate- and high-risk groups. My presentation will describe results from the Canadian Prostate Cancer Genome Network (CPC-GENE), the world's largest prostate cancer genomics project. CPC-GENE is sequencing the somatic and germline genomes of 500 intermediate-risk prostate cancers, along with epigenetic, transcriptomic and proteomic profiles. I will first discuss the intra-tumoural heterogeneity of these tumours, which shows profound genomic and micro-environmental heterogeneity. I will then link this variability directly to patient outcome, demonstrating the benefit of linking tumour hypoxia and somatic mutation profiles to robustly predict patient survival. Finally, I will discuss the challenges in translating sequencing-based assays into clinical practice. The ICGC-TCGA DREAM Somatic Mutation Calling Challenge provides the first rigorous investigation of the error profiles of sequencing studies, and I will discuss the startling degree of heterogeneity introduced by variability in analysis. Challenge-style benchmarking evaluations are increasingly critical, and I close by discussing how moving these into the cloud provides a framework for robust, rapid and reproducible comparison and optimization of algorithms for computational cancer biology.

Share this abstractTweet about this on TwitterPrint this pageShare on FacebookEmail this to someoneShare on LinkedIn